Stryker Corporation

NYSE:SYK

Medical - Devices

Healthcare
$318.15 +3.08%

+$9.29 today

Market cap
$121.12B
Beta
0.79
P/E (TTM)
35.6
EPS (TTM)
$8.72
Dividend yield
1.11%
52W Low $281.00High $404.87

Volume 3.25M

Average 2.49M

SYK Operating Cash Flow

Cash generated by the company's core business operations during the period.

Stryker CorporationNYSE: SYK

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow grows, but more slowly than its trailing trend

Q2 FY2026 operating cash flow of $1.26B rose 13.5% year over year, behind the +15.9% change in trailing-twelve-month operating cash flow. Sequentially, it rose 117.0% from the prior quarter. Over 3 fiscal years it compounded at +24.3% a year.

Context

  • Operating cash flow amounted to 20.1% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Operating cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.5% toward the trailing-twelve-month pace of +15.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.26B+117.0% QoQ
Last fiscal yearDec 2025
$5.04B+18.9% YoY
LTMJun 2026
$5.53B+15.9% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.5%——
1 year+18.9%——
3-year CAGR+24.3%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
5.04B USD
Year-over-year change
+18.9%
4-year CAGR
+11.5%

Operating Cash Flow vs competitors

How SYK compares with its peers on the latest reported figures

  • SYK's LTM Jun 2026 operating cash flow of $5.53B is the 2nd largest of the 11 companies compared; the peer median is $192.73M.
  • Its year-over-year change of +15.9% is the 7th highest of 11, against a peer median of +32.3%.
  • Operating cash flow amounts to 21.4% of revenue for SYK, versus a peer median of 10.5%.
SYK Competitors Peer median
Operating Cash Flow for SYK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$8.04B +12.4%+6.7%21.4%
SYKStryker CorporationLTM Jun 2026$5.53B +15.9%+24.3%21.4%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$1.74B +4.8%+9.7%20.5%
SNNSmith & Nephew plcFY2025$1.29B +30.2%+40.0%20.8%
GMEDGlobus Medical, Inc.LTM Jun 2026$910.39M +36.0%+61.6%28.9%
ENOVEnovis CorporationLTM Apr 2026$242.84M +64.0%—10.7%
CNMDCONMED CorporationLTM Mar 2026$142.63M -20.5%+72.3%10.4%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$71.44M -30.2%-42.5%4.3%
ATECAlphatec Holdings, Inc.LTM Mar 2026$51.56M +558.2%—6.6%
OFIXOrthofix Medical Inc.LTM Mar 2026$34.91M +34.3%—4.2%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$9.15M +288.2%—7.5%
Peer median (excluding SYK) $192.73M+32.3%+24.9%10.5%

Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.99B2.36B3.17B2.99B3.25B
Depreciation & Amortization990M998M1.03B1.05B1.19B
Deferred Income Tax(237M)58M(206M)(370M)392M
Stock-Based Compensation171M168M205M229M243M
Change in Working Capital279M(732M)(500M)(683M)(373M)
Accounts Receivables(377M)(579M)(175M)(321M)127M
Inventory(189M)(762M)(797M)(206M)(297M)
Accounts Payables329M290M77M192M94M
Other Working Capital516M319M395M(348M)(297M)
Other Non-Cash Items66M(226M)19M1.02B343M
Operating Cash Flow3.26B2.62B3.71B4.24B5.04B
Capital Expenditures(525M)(588M)(575M)(755M)(761M)
Acquisitions (Net)(339M)(2.56B)(390M)(1.63B)(4.8B)
Purchases of Investments(49M)(52M)(52M)(808M)0
Sales of Investments55M240M54M148M750M
Other Investing Activities(1M)39M1M43M(60M)
Investing Cash Flow(859M)(2.92B)(962M)(3B)(4.87B)
Debt Repayment(1.15B)472M(277M)940M1.58B
Common Stock Issued00000
Common Stock Repurchased(114M)(122M)(155M)(195M)(149M)
Dividends Paid(950M)(1.05B)(1.14B)(1.22B)(1.28B)
Other Financing Activities(148M)(48M)(23M)(51M)(33M)
Financing Cash Flow(2.37B)(749M)(1.59B)(525M)113M
Effect of Forex Changes(38M)(51M)(28M)(36M)68M
Net Change in Cash1M(1.1B)1.13B681M359M
Free Cash Flow2.74B2.04B3.14B3.49B4.28B

Stryker Corporation

NYSE:SYK

Intrinsic Alpha fair value

Locked

Current Price

$318.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.